Lipocine is developing an oral progesterone for Hormone Replacement Therapy (HRT). LPCN 1002 utilizes progesterone that is endogenous to the body and is generally considered safer than available synthetic forms.

LPCN 1002 is a peanut oil free solid unit dosage form with superior bioavailability. This product is targeted for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. LPCN 1002 is also indicated for use in secondary amenorrhea.